|
Alzheimer's Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The HBP joins a handful of online registries worldwide that assess and monitor a large cohort of individuals at risk of AD.
|
30909237 |
2019 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
While the inhibitor of HDLBP has been reported, our work suggested a promising potential of targeting HDLBP to improve the treatment of fatal SCLC and a powerful tool of using cell-SELEX in cancer medicine.
|
31233742 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our pilot data suggest decreased vigilin protein expression, along with shift from the nucleus to the cytoplasmic location, in the transition to ductal carcinoma in situ.
|
30292064 |
2019 |
|
Brain Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Vigilin is increased in ischemia brain slices and exhibits enhanced release from cultured hippocampal neurons after oxygen glucose deprivation in vitro.
|
30993971 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Attenuating HDLBP expression with siRNA inhibited proliferation and metastasis of SCLC cells in vitro and tumor formation in vivo.
|
31233742 |
2019 |
|
Small cell carcinoma of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
While the inhibitor of HDLBP has been reported, our work suggested a promising potential of targeting HDLBP to improve the treatment of fatal SCLC and a powerful tool of using cell-SELEX in cancer medicine.
|
31233742 |
2019 |
|
Hepatocellular Adenoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, iso- or hyperintensity of hepatocellular adenomas on HBP does not necessarily correspond to an increased hepatospecific contrast-agent uptake.
|
30937584 |
2019 |
|
Capillary hyperpermeability
|
0.010 |
Biomarker
|
disease |
BEFREE |
HBP mediates capillary hyperpermeability experimentally.
|
30447193 |
2019 |
|
Mirizzi Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We critically evaluated the impact of the systematic adoption of MI-HBP surgery on the surgical outcomes of MS.
|
31529332 |
2019 |
|
Inflammatory Myofibroblastic Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Target appearance on later phases, such as TP and HBP, and DWI target appearance were commonly in ICCs, but rare in IMTs.
|
30515535 |
2019 |
|
Intrahepatic Cholangiocarcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Meanwhile, most of the ICCs showed homogeneous hypointensity on T1WI (100%), a hyperenhancing rim on AP, late target appearance on TP (n = 32, 94.1%) and HBP (n = 32, 94.1%).
|
30515535 |
2019 |
|
Ischemic stroke
|
0.010 |
Biomarker
|
disease |
BEFREE |
Aptamer LCW17 and vigilin may potentially be applied to define the molecular mechanism underlying ischemic stroke, as well as its diagnosis.
|
30993971 |
2019 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
While the inhibitor of HDLBP has been reported, our work suggested a promising potential of targeting HDLBP to improve the treatment of fatal SCLC and a powerful tool of using cell-SELEX in cancer medicine.
|
31233742 |
2019 |
|
Steatohepatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
In IHCA, tumor hyperintensity on precontrast images and the underlying steatosis likely explain such iso- or hyperintensity, which do show reduced HBP contrast-agent uptake.
|
30937584 |
2019 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF.
|
28985325 |
2018 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
we studied the feasibility and efficacy of an integrated telerehabilitation home-based programme (Telereab-HBP), 4 months long, in patients with combined COPD and CHF.
|
28985325 |
2018 |
|
Meningitis, Bacterial
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Both HBP levels were significantly higher in patients with bacterial meningitis.
|
30166267 |
2018 |
|
Regurgitation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Other improvements after HBP upgrade included mitral valve regurgitation, serum brain natriuretic peptide concentrations, cardiothoracic ratios, and New York Heart Association functional class (P < .01 for all).
|
29081396 |
2018 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
HBP has a major role in the pathophysiology of severe bacterial infections and thus represents a potential diagnostic marker and a target for the treatment of sepsis.
|
28370601 |
2017 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Since its identification 30 years ago, vigilin has been shown to bind over 700 mRNAs and has been associated with cancer progression and cardiovascular disease.
|
28975734 |
2017 |
|
Erythema
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
After two weeks of treatment with HBP Lotion, 44.5% of the HBP Lotion treated subjects in each study achieved (a) treatment "success" (ie, an IGA score of 0=clear or 1=almost clear and >2 grade improvement compared to baseline) and (b) a notable reduction in plaque elevation, erythema, scaling, and pruritus.
|
28301619 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified a set of genes including CTBP2, NADK, AZU1, CTSH, FSTL1, and HDLBP showing the highest accuracy more than 69.44 % to classify TKI response in CML patients.
|
27534394 |
2016 |
|
Multiple Chronic Conditions
|
0.010 |
Biomarker
|
disease |
BEFREE |
Human vigilin, a multi-KH-domain nucleic acid-binding protein, is associated with alpha satellites of centromeres.
|
26032007 |
2015 |
|
Toxic Epidermal Necrolysis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified HDLBP, which encodes the RNA-binding protein vigilin, as a candidate tumor suppressor deleted at 2q37.3 in greater than one out of ten tumors across multiple tissues of origin.
|
25129143 |
2014 |
|
Liver Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We discovered that vigilin expression increased progressively from the liver cirrhosis tissue to adjacent non-tumor liver tissue and then to HCC tumor cells.
|
24676454 |
2014 |